論文

査読有り
2010年6月

New orally bioavailable 2-aminobenzamide-type histone deacetylase inhibitor possessing a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group

BIOORGANIC & MEDICINAL CHEMISTRY
  • Shingo Kiyokawa
  • ,
  • Yoshiyuki Hirata
  • ,
  • Yasuo Nagaoka
  • ,
  • Makio Shibano
  • ,
  • Masahiko Taniguchi
  • ,
  • Masahide Yasuda
  • ,
  • Kimiye Baba
  • ,
  • Shinichi Uesato

18
11
開始ページ
3925
終了ページ
3933
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.bmc.2010.04.033
出版者・発行元
PERGAMON-ELSEVIER SCIENCE LTD

New 2-aminobenzamide-type histone deacetylase (HDAC) inhibitors were synthesized. They feature a sulfur-containing bicyclic arylmethyl moiety-a surface recognition domain introduced to increase in cellular uptake-and a substituted tert-amino group which affects physicochemical properties such as aqueous solubility. Compound 22 with a (2-hydroxyethyl)(4-(thiophen-2-yl)benzyl)amino group reduced the volume of human colon cancer HCT116 xenografts in nude mice to T/C 67% by oral administration at 45 mg/kg, which was comparable to the rate (T/C 62%) for a positive control, MS-275. Western blot analyses as well as cell cycle and TUNEL assays by flow cytometry suggested that the two compounds inhibited the growth of cancer cells via similar mechanisms. (C) 2010 Elsevier Ltd. All rights reserved.

リンク情報
DOI
https://doi.org/10.1016/j.bmc.2010.04.033
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/20452226
Web of Science
https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=JSTA_CEL&SrcApp=J_Gate_JST&DestLinkType=FullRecord&KeyUT=WOS:000278078600032&DestApp=WOS_CPL
ID情報
  • DOI : 10.1016/j.bmc.2010.04.033
  • ISSN : 0968-0896
  • PubMed ID : 20452226
  • Web of Science ID : WOS:000278078600032

エクスポート
BibTeX RIS